These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 390480)

  • 1. The bone marrow in polycythemia vera.
    Ellis JT; Peterson P
    Pathol Annu; 1979; 14 Pt 1():383-403. PubMed ID: 390480
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Studies of the bone marrow in polycythemia vera and the evolution of myelofibrosis and second hematologic malignancies.
    Ellis JT; Peterson P; Geller SA; Rappaport H
    Semin Hematol; 1986 Apr; 23(2):144-55. PubMed ID: 3704666
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Contribution of bone marrow biopsy in the diagnosis and prognosis of polycythemia vera.
    de Mascarel A
    Nouv Rev Fr Hematol (1978); 1994 Apr; 36(2):165-6. PubMed ID: 8036134
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The value of bone marrow histology in differentiating between early stage Polycythemia vera and secondary (reactive) Polycythemias.
    Thiele J; Kvasnicka HM; Zankovich R; Diehl V
    Haematologica; 2001 Apr; 86(4):368-74. PubMed ID: 11325641
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The impact of peripheral blood values and bone marrow findings on prognosis for patients with essential thrombocythemia and polycythemia vera.
    Abdulkarim K; Ridell B; Johansson P; Kutti J; Safai-Kutti S; Andréasson B
    Eur J Haematol; 2011 Feb; 86(2):148-55. PubMed ID: 21059102
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Polycythemia rubra vera versus secondary polycythemias. A clinicopathological evaluation of distinctive features in 199 patients.
    Thiele J; Kvasnicka HM; Muehlhausen K; Walter S; Zankovich R; Diehl V
    Pathol Res Pract; 2001; 197(2):77-84. PubMed ID: 11261821
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Polycythemia vera as a multiphasic clonal panmyelopathy: diagnostic profile, chronic pathological progression and effect of therapy on the survival of 74 cases].
    Sánchez Fayos J; Prieto E; Román A; Soto de Ozaeta C; Nevado I; Richart A; Chica E; Loscertales J; Calabuig T; Benítez J; Outeiriño J
    Sangre (Barc); 1996 Dec; 41(6):447-57. PubMed ID: 9148422
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Histopathology in the diagnosis and classification of acute myeloid leukemia, myelodysplastic syndromes, and myelodysplastic/myeloproliferative diseases.
    Orazi A
    Pathobiology; 2007; 74(2):97-114. PubMed ID: 17587881
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Postpolycythemic myeloid metaplasia in patients with polycythemia vera].
    Spasojević J; Pejin D; Stajnic S
    Med Pregl; 1997; 50(5-6):224-8. PubMed ID: 9297056
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Myelofibrosis--what's in a name? Consensus on definition and EUMNET grading.
    Thiele J; Kvasnicka HM
    Pathobiology; 2007; 74(2):89-96. PubMed ID: 17587880
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Prognostic value of bone marrow biopsy in chronic myeloproliferative disorders].
    Bettini R; Marzetta K; Miglioranza A; Redaelli S; Maino C; Maffiolini A; Gorini M
    Recenti Prog Med; 2003; 94(7-8):314-20. PubMed ID: 12868237
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bone marrow features of diagnostic impact in erythrocytosis.
    Thiele J; Kvasnicka HM; Diehl V
    Ann Hematol; 2005 Jun; 84(6):362-7. PubMed ID: 15803315
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Relevance of bone marrow features in the differential diagnosis between essential thrombocythemia and early stage idiopathic myelofibrosis.
    Thiele J; Kvasnicka HM; Zankovich R; Diehl V
    Haematologica; 2000 Nov; 85(11):1126-34. PubMed ID: 11064463
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Prognostic value of bone and bone marrow lesions of primary myeloid metaplasia].
    Chelloul N; Jacquillat C; Brière J; Laval-Jeantet M; Vorhauer-Atlan W
    Nouv Presse Med; 1975 Dec; 4(43):3060-2. PubMed ID: 1223788
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Transplant decision-making strategies in the myeloproliferative disorders.
    Fruchtman SM
    Semin Hematol; 2003 Jan; 40(1 Suppl 1):30-3. PubMed ID: 12682880
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Jamshidi biopsy in clinical hematology. Method, indications and results of over 1,000 completed biopsies with special reference to chronic myeloproliferative diseases].
    Seewann HL
    Wien Med Wochenschr Suppl; 1986; 100():1-24. PubMed ID: 3471009
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Follow-up study on bone marrow reticulin fibrosis in AML.
    Thiele J; Grashof K; Fisher R
    Anal Cell Pathol; 1991 Jul; 3(4):225-31. PubMed ID: 1883746
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Megakaryopoiesis and myelofibrosis in chronic myeloid leukemia after allogeneic bone marrow transplantation: an immunohistochemical study of 127 patients.
    Thiele J; Kvasnicka HM; Beelen DW; Flucke U; Spoer C; Paperno S; Leder LD; Schaefer UW
    Mod Pathol; 2001 Feb; 14(2):129-38. PubMed ID: 11235904
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Myelofibrosis in the myeloproliferative disorders.
    Ellis JT; Peterson P
    Prog Clin Biol Res; 1984; 154():19-42. PubMed ID: 6382293
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Morphometric study of the bone marrow in polycythemia vera following interferon-alpha therapy.
    Franco V; Florena AM; Aragona F; Campesi G
    Pathol Res Pract; 1993 Feb; 189(1):52-7. PubMed ID: 8516217
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.